Mednax (MD)

Healthcare · Medical Care Facilities
$26.64 +1.52% on the day Market cap $2.0B 52-week range $15.70 to $27.94 Prices as of Oct 11, 2026

What the price implies

A reverse DCF: instead of guessing a fair value, it asks what growth today's price already assumes. How it works.

Mednax's free cash flow isn't comparable to its market value here, so a cash-flow reverse DCF doesn't give a meaningful answer. The Modeling tab works from revenue and margins instead.

Fundamental grade

C

Five factors scored 1 to 9 from MD's latest numbers, weighted into one grade. It describes the business, not whether the stock is a buy.

Valuation8
Profitability6
Growth4
Financial health3

Results from SEC filings

Fiscal years, from Mednax's 10-K filings. Ten years of the full income statement, balance sheet and cash flow.

Fiscal year20212022202320242025
Revenue$1.9B$2.0B$2.0B$2.0B$1.9B
Net income$131M$66M-$60M-$99M$165M
Free cash flow—————
EPS (diluted)$1.53$0.79-$0.73-$1.19$1.94
Operating margin10.6%8.8%0.37%-3.4%10.9%

Where the revenue comes from

Revenue by products, fiscal 2025. Every breakdown, year by year.

Net patient service revenue$1.6B85%
Hospital contract administrative fees$271M14%
Product and Service, Other$12M1%

Superinvestors who own MD

From each investor's latest 13F filing (what a 13F shows). 3 of the investors we track hold it.

InvestorLast quarterValue% of portfolioQuarter
Cliff Asness
AQR Capital Management
Trimmed $12M0.00%Q2 2026
Charles Brandes
Brandes Investment Partners, LP
Trimmed $10M0.07%Q2 2026
Joel Greenblatt
Gotham Asset Management
Trimmed $2M0.00%Q2 2026

Insider buying

Open-market purchases by Mednax's executives and directors in the last 12 months, from SEC Form 4 filings. What insider buying tells you.

No open-market insider purchases of MD in the last 12 months. Most insider activity is selling and option exercises, which aren't shown here.

Get an alert at your buy price

Pick the price you'd be interested at. We'll email you when MD trades at or below it.

$

New accounts get 7 days of Pro, price alerts included. No card needed.

In the full deep dive

DCF fair value per share
Yearly return (IRR) at today's price
Growth implied by revenue and margins
15+ years of statements and quarters

Questions

Are Mednax insiders buying the stock?

No open-market insider purchases of MD in the last 12 months, according to SEC Form 4 filings.

Which superinvestors own Mednax?

3 of the superinvestors Investingly tracks hold MD in their latest 13F, including Cliff Asness, Charles Brandes, Joel Greenblatt.

Prices and ratios as of Oct 11, 2026; statements from SEC filings. Information only, not investment advice. Superinvestor holdings come from 13F filings, which are filed up to 45 days after each quarter ends.